RSPI Stock Overview
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
RespireRx Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0009 |
| 52 Week High | US$0.019 |
| 52 Week Low | US$0.0006 |
| Beta | 0.53 |
| 1 Month Change | 0% |
| 3 Month Change | -25.00% |
| 1 Year Change | -70.00% |
| 3 Year Change | -97.20% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| RSPI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -2.2% | -3.7% |
| 1Y | -70.0% | 11.6% | 20.5% |
Return vs Industry: RSPI underperformed the US Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: RSPI underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| RSPI volatility | |
|---|---|
| RSPI Average Weekly Movement | 28.0% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RSPI's share price has been volatile over the past 3 months.
Volatility Over Time: RSPI's weekly volatility has decreased from 35% to 28% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 2 | Arnold Lippa | www.respirerx.com |
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company’s lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea.
RespireRx Pharmaceuticals Inc. Fundamentals Summary
| RSPI fundamental statistics | |
|---|---|
| Market cap | US$774.68k |
| Earnings (TTM) | -US$2.17m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs RSPI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RSPI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.17m |
| Earnings | -US$2.17m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0028 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -22.6% |
How did RSPI perform over the long term?
See historical performance and comparison